Statistical considerations and analysis
migraine
MIGRAINE
Sample size calculations were based on the difference between two unpaired groups reporting migraine attacks. After administration of CGRP, we assumed that 51% of participants would report migraine attack in the placebo-treatment arm and 20% in the active-treatment arm. After administration of cilostazol, we assumed that 66% of participants would report migraine attack in the placebo-treatment arm and 20% in the active-treatment arm. These assumptions were based on previous migraine provocation studies, in which ∼66% of participants with migraine developed attacks after administration of CGRP and ∼86% after cilostazol,The primary end point was the incidence of migraine attacks in a 12-h observational period after administration of experimental triggers.